首页> 美国卫生研究院文献>Biomedicine Hub >Precision Medicine in Oncology and Immuno-Oncology: Where We Stand and Where Were Headed
【2h】

Precision Medicine in Oncology and Immuno-Oncology: Where We Stand and Where Were Headed

机译:肿瘤学和免疫肿瘤学中的精密医学:我们的立场和未来的方向

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Precision medicine has only been a clinical reality only since the start of the 21st century, spurred on by the coevolution of science and technologies, as well as the increasing medical needs of aging societies of industrialized countries. Its overarching objective, from the perspective of the pharmaceutical and diagnostic industry, is to develop innovative therapeutic “concepts” with increased value for patients in a global health economy context. This article analyzes the recent advances and remaining challenges from a research, medical, and regulatory perspective in the development and introduction of precision medicine in oncology, more precisely in immuno-oncology.
机译:直到21世纪初,由于科学技术的共同发展以及工业化国家老龄化社会对医疗的需求不断增加,精密医学才成为临床现实。从制药和诊断行业的角度来看,其首要目标是开发创新的治疗“概念”,在全球卫生经济的背景下为患者增加价值。本文从研究,医学和法规的角度分析了肿瘤学(更确切地说是免疫肿瘤学)的精确医学的发展和引入方面的最新进展和尚存的挑战。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号